The year 2012 has been a great one for approvals for PharmaLogic. Four products on which we made substantial contributions were approved in the U.S. : iStent® Trabecular Micro-Bypass Stent, Jetrea® (ocriplasmin), Kyprolis® (carfilzomib), and Myrbetriq® (mirabegron).